Abstract
To establish whether quantitative111In antimyosin uptake can be used to predict infarct age, we studied the heart-lung ratio in 107 images from 90 patients at various intervals following a Q-wave infarction. Imaging was performed 24 hours following111In antimyosin injection. The HLR was measured as the ratio of the maximum counts in the infarcted myocardium to the adjacent lung background. The ratio ranged from 1.26 to 3.87, and declined with increasing infarct age. Infarcts were classified on the basis of age as type I (< 3 days old), type II (<14 days), and type III (<90 days). True positive and false positive rates (TPR and FPR), and test-likelihood ratio calculations were performed for HLR thresholds ranging from 1 to 4, for the three infarct types. A FPR of 0% and likelihood ratio of infinity was obtained at a HLR threshold of 2.3 for type I infarcts (TPR 40.8%); at a HLR threshold of 2 for type II infarcts (TPR 50.6%), and a threshold of 1.8 for type III infarcts (TPR 52.6%). The likelihood of each infarct type can be estimated directly from the HLR for values below the above thresholds. These results show that quantitative111In-antimyosin imaging may be used to predict infarct age.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Khaw BA, Strauss HW, Pohost GM, Fallon JT, Katus HA, Haber E. Relation of immediate and delayed thallium-201 distribution to localization of iodine-125 antimyosin anti-body in acute experimental myocardial infarction. Am J Cardiol 1983; 51: 1428–32.
Jain D, Lahiri A, Crawley JCW, Raftery EB. Postmortem correlation between histopathologic and autoradiographic extent of myocardial necrosis detected by111In- antimyosin imaging in a patient with acute myocardial infarction. Am J Cardiac Imaging 1988; 2: 158–61.
Jain D, Crawley JC, Lahiri A, Raftery EB. Indium-111- antimyosin images compared with triphenyl tetrazolium chloride staining in a patient six days after myocardial in- farction. J Nucl Med 1990; 31: 231–33.
Hendel RC, McSherry BA, Leppo JA. Myocardial uptake of indium-111-labeled antimyosin in acute subendocardial infarction: clinical, histochemical, and autoradiographic correlation of myocardial necrosis. J Nucl Med 1990; 31: 1851–53.
Khaw BA, Gold HK, Yasuda T, Leinbach RC, Kanke M, Fallon JT, Barlai Kovach M, Strauss HW, Sheehan F, Haber E. Scintigraphic quantification of myocardial necrosis in patients after intravenous injection of myosin-specific antibody. Circulation. 1986; 74: 501–8.
Antunes ML, Seldin DW, Wall RM, Johnson LL. Measurement of acute Q-wave myocardial infarct size with single photon emission computed tomography imaging of indium-111 antimyosin. Am J Cardiol 1989; 63: 777–83.
Volpini M, Giubbini R, Gei P, Cuccia C, Franzoni P, Riva S, Terzi A, Metra M, Bestagno M, Visioli O. Diagnosis of acute myocardial infarction by indium-111 antimyosin anti-bodies and correlation with the traditional techniques for the evaluation of extent and localization. Am J Cardiol 1989; 63: 7–13.
van Vlies B, Baas J, Visser CA, van Royen E, Delemarre BJ, Bot H, Dunning AJ. Predictive value of indium-111 antimyosin uptake for improvement of left ventricular wall motion after thrombolysis in acute myocardial infarction. Am J Cardiol 1989; 64: 167–71.
Carrio I, Berna L, Ballester M, Estorch M, Obrador D, Cladellas M, Abadal L, Ginjaume M. Indium-111 anti-myosin scintigraphy to assess myocardial damage in patients with suspected myocarditis and cardiac rejection. J Nucl Med 1988; 29: 1893–1900.
Obrador D, Ballester M, Carrio I, Berna L, Pons Llado G. High prevalence of myocardial monoclonal antimyosin antibody uptake in patients with chronic idiopathic dilated cardiomyopathy. J Am Coll Cardiol 1989; 13: 1289–93.
Liu XJ, Jain D, Senior R, Broadhurst P, Lahiri A.111In-Antimyosin imaging for the detection of myocardial infarction: a quantitative approach. Nucl Med Commun 1990; 11: 667–75.
Estorch M, Carrio I, Berna L, Martinez-Duncker C, Alonso C, Germa JR, et al. Indium-111-Antimyosin scintigraphy after doxorubicin therapy in patients with advanced breast cancer. J Nucl Med 1990; 31: 1965–9.
Ballester M, Obrador D, Carrio I, Auge JM, Moya C, Pons Llado G, et al. Indium-111-monoclonal antimyosin antibody studies after the first year of heart transplantation. Identification of risk groups for developing rejection during long-term follow-up and clinical implications. Circulation 1990; 82: 2100–7.
Jain D, Broadhurst P, Raval U, Crawley JCW, Lahiri A, Raftery EB. Late imaging of myocardial infarction with In-111 antimyosin antibodies. Eur J Nucl Med 1989; 15: 470–4.
Liu XJ, Jain D, Senior R, Leppo J, Raval U, Raftery EB, et al. A quantitative method for assessing age of myocardial infarction from antimyosin images [abstract]. J Nucl Med 1990; 31: 782A.
Matsumori A, Yamada T, Tamaki N, Kawai C, Watanabe Y, Yonekura Y, et al. Persistent uptake of Indium-111 antimyosin monoclonal antibody in patients with myocardial infarction. Am Heart J 1990; 120: 1026–30.
Tamaki N, Yamada T, Matsumori A, Yoshida A, Fujita T, Ohtani H, et al. Indium-111-Antimyosin antibody imaging for detecting different stages of myopcardial infarction: comparison with Technetium-99m-Pyrophosphate imaging. J Nucl Med 1990; 31: 136–42.
Bhattacharya S, Liu XJ, Senior R, Jain D, Leppo J, Lahiri A.111In antimyosin antibody uptake is related to the age of myocardial infarction. Am Heart J 1991. In press.
The International Collaborative Study Group. Reduction of infarct size with the early use of timolol in acute myocardial infarction. N Engt J Med 1984; 310: 9–15.
Kereikas DJ, Salmon MR, McAuley BJ, McAuley DB, Sheehan DJ, Simpson JB. Angioplasty for total coronary occlusion: experience in 76 consecutive patients. J Am Coll Cardiol 1985; 6: 526–33.
Wexman MP, Clark DA, Murphy MC, Rosen JF, Shaw RE, Stertzer SH, et al. Patient selection, complications and predictors of success in PTCA of total occlusions [Abstract]. Circulation 1985; 72: III Suppl: 141A.
Goldman L. Cardiac risks and complications of non-cardiac surgery. Ann Intern Med 1983; 98: 504.
Goldman L, Caldera DL, Nussbaum SR, Southwick FS, Krogstad D, Murray B, et al. Multifactorial index of cardiac risk in non-cardiac surgery. N Engl J Med 1977; 297: 845–50.
Sobel BE, Shell WE. Serum enzyme determinations in the diagnosis and assessment of myocardial infarction. Circulation 1972; 45: 471–82.
Mills RM, Young G, Gorlin R, Lesch M. Natural history of S-T segment elevation after acute myocardial infarction. Am J Cardiol 1975; 35: 609–14.
Thygesen K, Horder M, Lyager BN, Hyltoft PP. Evolution of ST segment and Q and R waves during early phase of inferior myocardial infarction. Acta Med Scand 1979; 205: 25–30.
Selwyn AP, Ogunro EA, Shillingford JP. Natural history and evolution of ST segment changes and MB CK release in acute myocardial infarction. Br Heart J 1977; 39: 988–94.
Yusuf S, Lopez R, Maddison A, Sleight P. Variability of electrocardiographic and enzyme evolution of myocardial infarction in man. Br Heart J 1981; 45: 271–80.
Weinstein MC, Fineberg HV. Clinical decision analysis. Philadelphia: W.B. Saunders Co., 1980: 37–74.
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Bhattacharya, S., Senior, R., Liu, X.j. et al. Quantitative111in antimyosin antibody imaging to predict the age of myocardial infarction. Int J Cardiac Imag 8, 103–107 (1992). https://doi.org/10.1007/BF01137531
Accepted:
Issue Date:
DOI: https://doi.org/10.1007/BF01137531